Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
- PEARL-1 and PEARL-2 trial investigators
Research output: Contribution to journal › Article › peer-review
74
Link opens in a new tab
Scopus
citations